Unknown

Dataset Information

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.


ABSTRACT: Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals (n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predomi

SUBMITTER: Schmidt T 

PROVIDER: S-EPMC8440177 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature